Philippe Gallay

Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). Recently, approved drug treatments for MASLD, including thyroid hormone receptor beta (THR-β) and glucagon-like pepti...